Lille, France; Cambridge, MA; May 11, 2022 - GENFIT (NasdaqandEuronext:GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with severe chronic liver diseases, today announced its cash position as of March 31, 2022 and revenues for the first three months of 2022.
Cash position
GENFIT Reports First Quarter 2022 Financial Information (Unaudited financial information under IFRS)
Globe Newswire - Press Release
All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here